At the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, MA, Depixus was awarded the prestigious Ignite Award for their groundbreaking MAGNA™ technology. This innovative technology is based on magnetic force spectroscopy, allowing for high-throughput analysis of dynamic biomolecular interactions. It is particularly useful for exploring challenging targets such as RNA and protein-protein interactions, providing valuable insights into disease mechanisms and accelerating the development of novel therapeutics.
Depixus was one of just 16 companies selected to participate in the SLAS2024 Innovation AveNEW program, which is a dedicated area for start-ups and emerging companies within the conference. From these 16 companies, the top eight were chosen as finalists for the Ignite Award. The award recognizes companies that are revolutionizing the life sciences with their innovative technologies. Participants were evaluated on various criteria including excellence in innovation, marketing presence, impact, funding, and balanced leadership.
MAGNA One is just one example of Depixus’s innovative technology offerings. It is a powerful tool that can help researchers overcome some of the most challenging targets in biology. The company’s CEO Gordon Hamilton expressed his excitement about winning the Ignite Award, emphasizing the importance of this technology in advancing our understanding of diseases where new treatments are desperately needed. Chief Commercial Officer Steve Klose added that this award marks a significant moment for Depixus as they launch their technology access program and roll out MAGNA One commercially.
For more information about Depixus or their MAGNA One instrument, visit depixus.com or contact Steve Klose at email@example.com